EMBO Molecular MedicineMolecular BiologyPeer-reviewed journal article
DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells.
Jeremy RichiD, Melanie Bennaroch, Laura Notel, Polina PatalakhiD, Julien Alberola, Fayez IssaiD, Paule OpoloniD, Olivia BawaiD, Windy RondofiD, Antonin MarchaisiD, Philippe DesseniD, Guillaume MeuriceiD, Morgane Le GalliD, Mélanie Polrot, Karine Ser‐Le Roux, Kamel MamchaouiiD, Nathalie M DroiniD, Hana RaslováiD, Pascal MaireiD, Birgit GeoergeriD, Iryna PirozhkovaiD
Abstract
We have recently identified the uncharacterized ZNF555 protein as a component of a productive complex, which is involved in the morbid function of the 4qA locus in facioscapulohumeral dystrophy. As a result of our current findings, ZNF555 is hereinafter referred to as DiPRO1 (Death, Differentiation and PROliferation related PROtein 1). In this study, we provide substantial evidence that DiPRO1 plays a role in human myoblast differentiation. It acts on regulatory binding regions of SIX1, which is a master regulator of myogenesis. We further describe the relevance of DiPRO1 in mesenchymal tumors, such as rhabdomyosarcoma (RMS) and Ewing sarcoma. DiPRO1 plays a repressor role in these tumors via the epigenetic regulators TIF1B and UHRF1 in order to maintain methylation of regulatory cis-elements and promoters. Loss of DiPRO1 eradicates cancer cells, by switching on a distinct transcriptional and epigenetic program. It consists of mimicking the host defense against the virus response by awakening the retrotransposable repeats (RE) and the ZNP/KZFP gene family. DiPRO1 also contributes to the balance of cellular decisions toward inflammation and/or apoptosis by controlling TNF- via NF-kappaB signaling. Finally, we demonstrate that mesenchymal cancer tumors are vulnerable in response to si/shDiPRO1-based nanomedicines, positioning DiPRO1 as a potential new target for therapeutic intervention. Summary O_FIG O_LINKSMALLFIG WIDTH=196 HEIGHT=200 SRC="FIGDIR/small/523169v1_ufig1.gif" ALT="Figure 1"> View larger version (49K): org.highwire.dtl.DTLVardef@146f1e5org.highwire.dtl.DTLVardef@b3265borg.highwire.dtl.DTLVardef@19b52fcorg.highwire.dtl.DTLVardef@654f6d_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: DNA methylation
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: statistical model
- approach: experimental assay
- Citations
- 2
- FWCI
- 0.27
- Field percentile
- 46th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PROX1 transcription factor is a master regulator of myogenic and oncogenic features of rhabdomyosarcoma
N. Y. Gizaw, P. Kallio, … R. Kivela·bioRxiv·Apr 19, 2020
- Loss of SMARCB1 evokes targetable epigenetic vulnerabilities in Epithelioid Sarcoma
Jia Xiang Jin, Fabia Fuchslocher, … Thomas G. P. Grünewald·癌症:英文版Peer-reviewed·Jan 20, 2025
- SIX1 Reprograms Myogenic Transcription Factors to Maintain the Rhabdomyosarcoma undifferentiated state
J. Y. Hsu, E. P. Danis, … H. L. Ford·bioRxiv·Apr 25, 2021
- KRAB zinc finger proteins ZNF587/ZNF417 protect lymphoma cells from replicative stress-induced inflammation
F. Martins, O. Rosspopoff, … D. Trono·bioRxiv·Mar 8, 2023
- Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity
C. Lian, C. Zhang, … G.-H. Wei·Signal Transduction and Targeted TherapyPeer-reviewed·Sep 28, 2024
- TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma
Anh Tuan Vuong, Aniket S. Joshi, … Ashok Kumar·OncogenePeer-reviewed·Apr 6, 2026